

Effects of Nonpharmaceutical COVID-19 Interventions on Pediatric Hospitalizations for Other Respiratory Virus Infections, Hong Kong Island

Appendix

Appendix Table. Annual rate of pediatric hospitalizations for viral respiratory infection/10,000 residents, Hong Kong Island, China, 2017–2020*

Virus, year	Hospitalizations (95% CI)							
	<6 mo	6 mo –<12 mo	<1 y	1–<2 y	2–<5 y	5–<10 y	10–<15 y	15–<18 y
HK Island	4,180	4,180	8,360	9,136	27,102	46,470	40,137	27,930
Population								
Influenza A								
2017	117.8 (82.0–163.8)	191.8 (145.3, 248.5)	154.8 (124.8–189.8)	141.6 (114.2–173.7)	133.4 (117.6–150.7)	58.4 (50.5–67.3)	19.6 (14.8–25.5)	8.6 (5.0–13.7)
2018	53.8 (30.8–87.4)	74.0 (46.4–112.1)	63.9 (45.2–87.8)	84.7 (63.8–110.2)	102.8 (88.9–118.1)	31.2 (25.4–37.8)	7.7 (4.8–11.7)	4.5 (2.1–8.6)
2019	117.8 (82.0–163.8)	134.6 (96.2–183.3)	126.2 (99.2–158.2)	144.7 (116.9–177.1)	145.3 (128.8–163.4)	51.5 (44.0–59.8)	18.6 (13.9–24.3)	9.1 (5.4–14.3)
2020	16.8 (5.5–39.3)	40.4 (20.9–70.5)	28.6 (16.7–45.8)	29.3 (17.6–45.7)	23.4 (17.0–31.2)	7.6 (4.9–11.2)	3.9 (1.9–6.9)	2.0 (0.5–5.2)
Influenza B								
2017	6.7 (0.8–24.3)	26.9 (11.6–53.0)	16.8 (8.1–30.9)	16.9 (8.5–30.3)	19.7 (14.0–27.1)	16.0 (12.0–21.0)	4.6 (2.4–7.8)	2.5 (0.8–5.9)
2018	30.3 (13.9–57.5)	67.3 (41.1–103.9)	48.8 (32.7–70.1)	77.0 (57.1–101.5)	78.4 (66.4–91.9)	52.7 (45.1–61.1)	15.8 (11.5–21.1)	5.0 (2.4–9.3)
2019	13.5	26.9	20.2	21.6	29.1	30.6	12.6	5.5

Virus, year	Hospitalizations (95% CI)							
	<6 mo	6 mo–<12 mo	<1 y	1–<2 y	2–<5 y	5–<10 y	10–<15 y	15–<18 y
	(3.7–34.5)	(11.6–53.0)	(10.4–35.3)	(11.8–36.2)	(22.0–37.7)	(24.9–37.1)	(8.8–17.5)	(2.8–9.9)
2020	0	0	0	1.5	1.6	0.6	1.4	0.5
	(0–12.4)	(0–12.4)	(0–6.2)	(0–8.6)	(0.3–4.6)	(0.1–2.2)	(0.4–3.6)	(0–2.8)
RSV								
2017	383.6	333.1	358.3	224.8	120.4	7.3	2.5	2.0
	(316.4–460.8)	(270.7–405.6)	(311.8–409.8)	(189.8–264.3)	(105.4–136.9)	(4.7–10.8)	(1.0–5.1)	(0.5–5.2)
2018	353.3	249.0	301.1	161.6	113.7	8.8	1.4	0.5
	(289.0–427.7)	(195.5–312.6)	(258.6–348.6)	(132.2–195.7)	(99.1–129.7)	(5.9–12.6)	(0.4–3.6)	(0–2.8)
2019	275.9	201.9	238.9	147.8	88.2	7.0	2.5	1.0
	(219.4–342.5)	(154.1–259.9)	(201.2–281.6)	(119.7–180.5)	(75.5–102.5)	(4.4–10.4)	(1.0–5.1)	(0.1–3.6)
2020	33.6	13.5	23.6	18.5	10.4	1.5	0	0
	(16.2–61.9)	(3.7–34.5)	(12.9–39.5)	(9.5–32.3)	(6.3–16.0)	(0.5–3.5)	(0–1.3)	(0–1.9)
Adeno								
2017	60.6	175.0	117.8	160.1	138.6	51.5	11.9	2.5
	(35.9–95.7)	(130.7–229.4)	(91.8–148.8)	(130.8–194.0)	(122.4–156.2)	(44.0–59.8)	(8.3–16.6)	(0.8–5.9)
2018	20.2	90.8	55.5	115.5	75.8	15.4	2.1	0.5
	(7.4–43.9)	(59.9–132.2)	(38.2–78.0)	(90.8–144.7)	(64.0–89.1)	(11.5–20.3)	(0.8–4.6)	(0–2.8)
2019	37.0	77.4	57.2	115.5	94.4	21.5	4.6	2.5
	(18.5–66.2)	(49.1–116.1)	(39.6–79.9)	(90.8–144.7)	(81.2–109.2)	(16.8–27.1)	(2.4–7.8)	(0.8–5.9)
2020	6.7	43.7	25.2	36.9	14.5	3.6	1.4	0.5
	(0.8–24.3)	(23.3–74.8)	(14.1–41.6)	(23.7–55.0)	(9.7–21.0)	(1.9–6.3)	(0.4–3.6)	(0–2.8)
Para 1–4								
2017	191.8	329.7	260.8	275.6	199.3	39.0	8.8	2.5
	(145.3–248.5)	(267.7–401.9)	(221.3–305.2)	(236.7–319.0)	(179.9–220.2)	(32.6–46.4)	(5.7–12.9)	(0.8–5.9)
2018	171.6	265.8	218.7	250.9	193.1	38.1	5.6	2.0
	(127.8–225.6)	(210.4–331.3)	(182.7–259.7)	(213.9–292.6)	(173.9–213.7)	(31.8–45.4)	(3.2–9.1)	(0.5–5.2)
2019	148.0	282.6	215.3	214.0	178.5	38.1	5.3	2.0

Virus, year	Hospitalizations (95% CI)							
	<6 mo	6 mo–<12 mo	<1 y	1–<2 y	2–<5 y	5–<10 y	10–<15 y	15–<18 y
	(107.6–198.8)	(225.4–349.9)	(179.6–256.0)	(179.9–252.7)	(160.2–198.4)	(31.8–45.4)	(2.9–8.7)	(0.5–5.2)
2020	26.9 (11.6–53.0)	53.8 (30.8–87.4)	40.4 (25.9–60.1)	36.9 (23.7–55.0)	24.4 (17.9–32.4)	6.4 (3.9–9.7)	2.1 (0.8–4.6)	2.0 (0.5–5.2)
HMPV								
2017	37.0 (18.5–66.2)	63.9 (38.5–99.8)	50.5 (34.1–72.1)	69.3 (50.5–92.7)	46.7 (37.6–57.4)	5.8 (3.5–9.0)	1.1 (0.2–3.1)	1.0 (0.1–3.6)
2018	67.3 (41.1–103.9)	107.7 (73.7–152.0)	87.5 (65.3–114.7)	92.4 (70.5–118.9)	72.1 (60.6–85.2)	11.5 (8.1–15.8)	3.5 (1.7–6.4)	0.5 (0–2.8)
2019	53.8 (30.8–87.4)	97.6 (65.3–140.1)	75.7 (55.2–101.3)	75.4 (55.8–99.7)	78.9 (66.8–92.5)	11.8 (8.4–16.1)	2.1 (0.8–4.6)	1.5 (0.3–4.4)
2020	0 (0–12.4)	13.5 (3.7–34.5)	6.7 (1.8–17.2)	1.5 (0–8.6)	1.6 (0.3–4.6)	0 (0–1.1)	0.4 (0–2.0)	0.5 (0–2.8)
EV/RV								
2017	434.1 (362.4–515.8)	632.6 (545.4–729.7)	533.3 (476.2–595.4)	511.1 (457.6–569.2)	327.5 (302.9–354.0)	83.2 (73.7–93.7)	22.8 (17.6–29.0)	10.1 (6.2–15.6)
2018	494.6 (417.9–581.4)	551.8 (470.6–643.1)	523.2 (466.7–584.7)	449.5 (399.4–504.1)	377.8 (351.3–406.3)	81.1 (71.7–91.4)	27.7 (21.9–34.5)	7.6 (4.2–12.5)
2019	376.9 (310.3–453.4)	461.0 (387.0–544.9)	418.9 (368.5–474.3)	424.9 (376.2–478.1)	327.5 (302.9–354.0)	91.4 (81.4–102.3)	27.7 (21.9–34.5)	7.6 (4.2–12.5)
2020	60.6 (35.9–95.7)	107.7 (73.7–152.0)	84.1 (62.4–110.9)	95.4 (73.2–122.4)	72.1 (60.6–85.2)	18.5 (14.1–23.7)	9.1 (6.0–13.4)	3.0 (1.1–6.6)

*RSV, respiratory syncytial virus; Adeno, adenovirus; para 1–4, parainfluenza virus types 1–4; HMPV, human metapneumovirus; EV/RV, enterovirus/rhinovirus.